High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab
High-dose brolucizumab was effective in patients who did not respond to standard-dose brolucizumab after switching from previous anti-VEGF agents. Increasing the dosage could offer sustained disease control and reduce the treatment burden for patients with refractory AMD.
Authors
- Soonil Kwon (ORCID: https://orcid.org/0000-0003-1543-981X)
- Bum‐Joo Cho (ORCID: https://orcid.org/0000-0002-0244-388X)
- Jinsoo Kim (ORCID: https://orcid.org/0000-0003-4392-5583)
- Min Seon Park
Institutions
- Hallym University (KR)
- Sacred Heart Hospital (NG)
- Hallym University Sacred Heart Hospital (KR)
Publication Details
- Journal
- Ophthalmology and Therapy
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1007/s40123-024-01022-w
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.54